These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1114 related items for PubMed ID: 19223699

  • 21. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials.
    Iaconis JP, Pitkin DH, Sheikh W, Nadler HL.
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S191-6. PubMed ID: 9126693
    [Abstract] [Full Text] [Related]

  • 22. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa.
    Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW.
    Microb Drug Resist; 2005 Feb; 11(1):68-74. PubMed ID: 15770098
    [Abstract] [Full Text] [Related]

  • 23. Antibiotic resistance in Pseudomonas aeruginosa: an Italian survey.
    Bonfiglio G, Carciotto V, Russo G, Stefani S, Schito GC, Debbia E, Nicoletti G.
    J Antimicrob Chemother; 1998 Feb; 41(2):307-10. PubMed ID: 9533479
    [Abstract] [Full Text] [Related]

  • 24. Antimicrobial resistance, virulence factors, and genotypes of Pseudomonas aeruginosa clinical isolates from Gorgan, northern Iran.
    Shahri FN, Izanloo A, Goharrizi MASB, Jamali A, Bagheri H, Hjimohammadi A, Ardebili A.
    Int Microbiol; 2022 Nov; 25(4):709-721. PubMed ID: 35697891
    [Abstract] [Full Text] [Related]

  • 25. Clinical, microbiologic, and epidemiologic characteristics of Pseudomonas aeruginosa infections in a University Hospital, Malatya, Turkey.
    Yetkin G, Otlu B, Cicek A, Kuzucu C, Durmaz R.
    Am J Infect Control; 2006 May; 34(4):188-92. PubMed ID: 16679175
    [Abstract] [Full Text] [Related]

  • 26. The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
    Erdem I, Kaynar-Tascioglu J, Kaya B, Goktas P.
    Int J Antimicrob Agents; 2002 Nov; 20(5):384-6. PubMed ID: 12431875
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
    Erdem I, Kucukercan M, Ceran N.
    Chemotherapy; 2003 Dec; 49(6):294-7. PubMed ID: 14671429
    [Abstract] [Full Text] [Related]

  • 29. In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains.
    Dundar D, Otkun M.
    Yonsei Med J; 2010 Jan; 51(1):111-6. PubMed ID: 20046523
    [Abstract] [Full Text] [Related]

  • 30. In vitro efficacy of various antibiotic combinations against Pseudomonas aeruginosa isolates.
    Nazli E, Zer Y, Eksi F.
    J Int Med Res; 2015 Apr; 43(2):217-25. PubMed ID: 25547417
    [Abstract] [Full Text] [Related]

  • 31. Empirical monotherapy with meropenem or combination therapy: the microbiological point of view.
    Garcinuño P, Santibañez M, Gimeno L, Sánchez-Bautista A, Coy J, Sánchez-Paya J, Boix V, Merino E, Portilla J, Rodríguez JC.
    Eur J Clin Microbiol Infect Dis; 2016 Nov; 35(11):1851-1855. PubMed ID: 27503076
    [Abstract] [Full Text] [Related]

  • 32. In-vitro effects of a combination of antipseudomonal antibiotics against multi-drug resistant Pseudomonas aeruginosa.
    Oie S, Sawa A, Kamiya A, Mizuno H.
    J Antimicrob Chemother; 1999 Nov; 44(5):689-91. PubMed ID: 10552987
    [Abstract] [Full Text] [Related]

  • 33. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
    Ludwig E, Konkoly-Thege M, Kuti JL, Nicolau DP.
    Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
    [Abstract] [Full Text] [Related]

  • 34. Bacteremia due to Pseudomonas aeruginosa: results from a 3-year national study in the Slovak Republic.
    Koprnova J, Beno P, Korcova J, Mrazova M, Grey E, Liskova A, Harnicarova A, Karvaj M, Koval S, Zak V, Danaj M, Streharova A, Mitterpachova E, Miklosko J, Ondrusova A, Riedl J, Kaiserova E, Prokopova V, Hornova M, Payer J, Rudinsky B, Pevalova L, Bencelova M, Hanzen J, Macekova L, Csölleyova J, Krcmery V.
    J Chemother; 2005 Oct; 17(5):470-6. PubMed ID: 16323434
    [Abstract] [Full Text] [Related]

  • 35. Antimicrobial therapy and control of multidrug-resistant Pseudomonas aeruginosa bacteremia in a teaching hospital in Taiwan.
    Leung CH, Wang NY, Liu CP, Weng LC, Hsieh FC, Lee CM.
    J Microbiol Immunol Infect; 2008 Dec; 41(6):491-8. PubMed ID: 19255693
    [Abstract] [Full Text] [Related]

  • 36. [Antimicrobial susceptibility of Pseudomonas aeruginosa isolated in Fukushima Prefecture].
    Niitsuma K, Saitoh M, Kojimabara M, Kashiwabara N, Aoki T, Tomizawa M, Maeda J, Kosenda T.
    Jpn J Antibiot; 2001 Feb; 54(2):79-87. PubMed ID: 11338681
    [Abstract] [Full Text] [Related]

  • 37. Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multiresistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ, Grecka P, Giamarellou H.
    Diagn Microbiol Infect Dis; 1997 Oct; 29(2):81-6. PubMed ID: 9368083
    [Abstract] [Full Text] [Related]

  • 38. Characteristics of carbapenem-resistant Pseudomonas aeruginosa strains in patients with ventilator-associated pneumonia in intensive care units.
    Vitkauskienė A, Skrodenienė E, Dambrauskienė A, Bakšytė G, Macas A, Sakalauskas R.
    Medicina (Kaunas); 2011 Oct; 47(12):652-6. PubMed ID: 22370463
    [Abstract] [Full Text] [Related]

  • 39. In-vitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa.
    Gerçeker AA, Gürler B.
    J Antimicrob Chemother; 1995 Oct; 36(4):707-11. PubMed ID: 8591946
    [Abstract] [Full Text] [Related]

  • 40. [Antimicrobial susceptibility of Pseudomonas aeruginosa isolated from urine at one hospital to mainly carbapenem and fluoroquinolone drugs].
    Watanabe Y, Fujiue Y, Yano S, Shimizu S, Muroki K, Doi M, Kuwabara M.
    Jpn J Antibiot; 2006 Apr; 59(2):65-71. PubMed ID: 16805317
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 56.